Sponsor Pipeline

Summit Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
3
Recruiting
4
Phase 3
3
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-05 NCT07228832
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With…		 Trial sites expanded: 140 -> 166 locations
2026-07-22 NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With…		 Trial sites expanded: 202 -> 270 locations
Active Trials by Phase
Phase 3
4
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05899608 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients Non-Small Cell Lung Cancer Recruiting
NCT06767514 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With… Non-Small Cell Lung Cancer Recruiting
NCT07228832 Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With… Metastatic Colorectal Cancer (CRC) Recruiting
NCT06396065 Phase III Study of AK112 for NSCLC Patients Non-Squamous Non-small Cell Lung Cancer Active, Not Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (3) Colorectal Cancer (1)
Get alerts when Summit Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free